Name PRICE MARKET CAPITALIZATION PRICE TO EARNINGS RATIO DIVIDEND YIELD SYMBOL EXCHANGE PRICE PERCENT DIFFERENCE YEAR TO DATE PRICE PERCENT DIFFERENCE 5 YEAR CHART 1 YEAR CHART

Progenics Pharmaceuticals Inc is an oncology company focused on developing and commercializing targeted medicines and artificial intelligence to treat cancer. Its portfolio includes AZEDRA (to treat malignant and recurrent pheochromocytoma and paraganglioma); 1404 and PyL (imaging agents for prostate cancer); 1404 Index and PyL (analytical tools for analysis and indexing of images for prostate cancer); 1095 (treatment of metastatic prostate cancer); PSMA ADC (treatment of metastatic castration-resistant prostate cancer); and EXINI boneBSI (an analytical Bone Scan Index tool from bone scintigraphy images, currently sold in Europe and Japan). Its partnered products are RELISTOR (sold in the U.S., EU, Australia, and Canada) to treat opioid-induced constipation, and the PRO 140 HIV treatment.

http://www.progenics.com


PGNX $4.33 -0.27 (-5.87%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 370 Million
EPS -0.17 P/E Ratio 0.00
Previous Earnings Thu, Nov 8, 2018
Latest Earnings Thu, Mar 14, 2019
Dividend --
Ex-Date --
Dividend Pay Date --
Dividend History --

4.33 0.37 0.00 0.00 PGNX NASDAQ -5.87 1.88 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=PGNX&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=PGNX&exchange=NASDAQ&chart=1

Symbol Surfing has been referenced on Barrons, CNN & Investor Place.

About | Blog | Advertising | Terms | info@symbolsurfing.com

Investing Quotes #Legendary


Information is provided "as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.

Some links on this website are advertisements and/or affiliate links and Symbol Surfing receives compensation.

©2019 Symbol Surfing All Rights Reserved. Privacy Policy | ^Top